| (a) An IDT may:
(1) consent to the following changes regarding administration
of a psychoactive medication subsequent to the initial consent for
the medication given by a surrogate consent committee, if such changes
pose no significant risk to an individual based on the judgment of
the prescribing health care professional and other health care professionals
involved in the individual's care:
(A) an increase or decrease in the dosage of the medication;
and
(B) a change of medication within the same therapeutic
drug class; and
(2) make a decision that involves risk to the individual
protection and rights not specifically reserved to a surrogate decision-maker
or a surrogate consent committee.
(b) An IDT's consent to a change regarding the administration
of a psychoactive medication, as described in subsection (a)(1) of
this section, is only valid until the expiration of the initial consent
by the surrogate consent committee.
(c) The IDT must document, in the individual's record,
a decision made in accordance with subsection (a) of this section,
including the deliberations of the IDT in reaching the decision.
|
| Source Note: The provisions of this §261.285 adopted to be effective July 1, 2007, 32 TexReg 3856; transferred effective October 1, 2020, as published in the Texas Register August 28, 2020, 45 TexReg 6127 |
